• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular Safety of the β3 -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial.
Abstract There have been concerns that treatment of overactive bladder with β3 -adrenoceptor agonists may potentially have detrimental cardiovascular (CV) side effects. We evaluated the CV safety of mirabegron, a β3 -adrenoceptor agonist, alone and in combination therapy with the antimuscarinic agent solifenacin. The SYNERGY trial was a multinational, multicenter, randomized, double-blind, parallel-group, placebo and active-controlled phase 3 trial. Patients were randomized to receive solifenacin 5 mg + mirabegron 50 mg (combination 5 + 50 mg), solifenacin 5 mg + mirabegron 25 mg (combination 5 + 2...
Source: The Journal of Clinical Pharmacology - April 12, 2018 Category: Drugs & Pharmacology Authors: White WB, Chapple C, Gratzke C, Herschorn S, Robinson D, Frankel J, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Weber MA Tags: J Clin Pharmacol Source Type: research

Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study
ConclusionsWe did not identify differences in the risk of cardiovascular events or mortality among users of individual antimuscarinic OAB drugs.
Source: European Journal of Clinical Pharmacology - November 13, 2017 Category: Drugs & Pharmacology Source Type: research